Emergent Renal And Hepatic Dysfunction (Dys) In A Real-World Cohort Of Advanced Melanoma (Amel) Patients (Pts) Receiving First Line (1l) Immune Checkpoint Inhibitors (Icis).

Susan Spillane,Amy P. Abernethy,Nicholas R Brown,Andrew N. Freedman,David Lenis,Kathleen Maignan,Angela B. Mariotto,Rebecca A. Miksad,Aracelis Z. Torres,Elad Sharon

JOURNAL OF CLINICAL ONCOLOGY（2018）

Cited 0|Views16

No score

Abstract

e21582Background: ICI trials report varying rates of renal and hepatic toxicity. We evaluated a real-world cohort of aMel pts with normal baseline renal and hepatic labs to identify changes consist...

Translated text

Key words

immune checkpoint inhibitors,advanced melanoma,hepatic dysfunction,real-world

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined